The effect of controversial reports on GlaxoSmithKline diabetes drug Avandia has had a positive effect on Takeda Pharmaceutical Co. Sales and demand for their diabetes treatment Actos have soared, leading to a three-month share value peak, according to data by Deutsche Bank AG.
Avandia has been cut from many doctor’s prescriptions lists following a New England journal of medicine report by scientists at Wake Forest University . The report indicated that Avandia led to a much higher incidence of heart attack. The Food and Drug Administration put out a warning for diabetics taking the drug and those about to be prescribed.
Actos is a major seller for Takeda, and accounts for around 25 per cent of their revenue per annum. It is the best selling product for the company, who are based in Osaka, Japan. Whether Avandia will recover remains to be see, and Glaxo bosses have expressed their confidence in the drug. Diabetic patients and healthcare teams may be hesitant over its influence on the heart for some time.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…